The potential of both mRNA technologies and lipid nanoparticle (LNPs) have been highlighted throughout the COVID-19 pandemic. With the upsurge in the mRNA technologies in clinical pipelines globally, 2022 will be a year dominated by mRNA-based products.
In this commentary, Bill Vincent, Founder and Executive Chairman at Genezen, highlights mRNA technologies as the innovation disrupting the biopharmaceutical industry and discusses how LNPs could further impact drug product development in future.
Read the full article here:
